The earnings call presented significant advancements in the clinical pipeline and AI platform, highlighting strategic initiatives to maximize shareholder value and financial discipline. However, the need for additional funding and potential risks associated with AI implementation were noted as challenges.

Company Guidance -

Q2 2025

During the First Quarter 2025 Earnings Call, Lantern Pharma provided extensive guidance on its strategic initiatives and financial metrics. The company highlighted significant progress in its clinical pipeline, particularly with LP-184, which has advanced to cohort 12 in its Phase 1a trial with an expected enrollment of 62 to 65 patients by June 2025. This trial aims to address various solid tumors, and early indications show clinical activity at higher doses. Lantern also emphasized the dual fast track designations for LP-184 in glioblastoma and triple-negative breast cancer, presenting major market opportunities. The company reported a net loss of $4.5 million for Q1 2025, a decrease from $5.4 million in the previous year, reflecting operational efficiency improvements, while maintaining a cash position of $19.7 million. Additionally, Lantern plans to commercialize its radar AI platform, now expanded to 200 billion oncology-focused data points, offering new revenue streams through a freemium model. With strategic partnerships and disciplined capital management, the company projects a financial runway until mid-May 2026.

Advancement in Clinical Pipeline

The Phase 1a trial for LP-184 has progressed well, with enrollment now through cohort 12. The trial is expected to complete enrollment with 62 to 65 patients by June 2025, and early indications of clinical activity at higher dose levels align with preliminary pharmacokinetic data.

AI Platform Expansion

The radar AI platform expanded to over 200 billion oncology-focused data points. The platform is being opened to the scientific community on a module-by-module basis, starting with a freemium approach to drive collaborations and economic opportunities.

Financial Discipline

Lantern Pharma ended the quarter with approximately $19.7 million in cash, cash equivalents, and marketable securities, providing an expected operating runway through at least mid-May 2026. The quarterly net loss decreased to approximately $4.5 million from $5.4 million in the same period last year.

Strategic Initiatives for Shareholder Value

Lantern Pharma is engaging in discussions for potential partnerships, including licensing agreements, technology partnerships, and co-development opportunities to accelerate the pipeline.

Innovative AI Modules

Introduction of an AI-powered module to improve antibody-drug conjugate development, capable of reducing timelines by 30%-50% and preclinical costs by up to two-thirds.

Lantern Pharma (LTRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LTRN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	-0.44 / -	-0.46	―	―	―
May 15, 2025	2025 (Q1)	-0.49 / -0.42	-0.51	17.65% (+0.09)
Mar 27, 2025	2024 (Q4)	-0.51 / -0.54	-0.39	-38.46% (-0.15)
Nov 07, 2024	2024 (Q3)	-0.56 / -0.42	-0.29	-44.83% (-0.13)
Aug 08, 2024	2024 (Q2)	-0.55 / -0.46	-0.44	-4.55% (-0.02)
May 09, 2024	2024 (Q1)	-0.43 / -0.51	-0.36	-41.67% (-0.15)
Mar 18, 2024	2023 (Q4)	-0.40 / -0.39	-0.31	-25.81% (-0.08)
Nov 08, 2023	2023 (Q3)	-0.48 / -0.29	-0.21	-38.10% (-0.08)
Aug 09, 2023	2023 (Q2)	-0.43 / -0.44	-0.41	-7.32% (-0.03)
May 09, 2023	2023 (Q1)	-0.48 / -0.36	-0.38	5.26% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LTRN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2025	$4.06	$3.86	-4.93%
Mar 27, 2025	$3.72	$3.55	-4.57%
Nov 07, 2024	$3.42	$3.84	+12.28%
Aug 08, 2024	$4.23	$3.90	-7.80%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lantern Pharma, Inc. (LTRN) report earnings?

Lantern Pharma, Inc. (LTRN) is schdueled to report earning on Aug 06, 2025, Before Open (Confirmed).

What is Lantern Pharma, Inc. (LTRN) earnings time?

Lantern Pharma, Inc. (LTRN) earnings time is at Aug 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LTRN EPS forecast?

LTRN EPS forecast for the fiscal quarter 2025 (Q2) is -0.44.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing